
Shilpa Medicare's Net Block Surpasses Rs 1,400 Crore by FY25
The story in brief
Shilpa Medicare's net block rose from Rs 558 crore in FY19 to over Rs 1,400 crore by FY25, reflecting a decade-long investment. APIs and formulations already contribute significantly to revenue, while peptides, biosimilars, and CDMO represent future growth. The company has entered the ADC space with SBPL01, entering human studies in FY27, and its US partner Amneal launched PEMRYDI RTU in April 2024.